Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US

 Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US

Pfizer and BioNTech Reports First Patient Dosing in P-I/II Study with BNT162 for COVID-19 in the US

Shots:Shots:

  • The Phase 1/2 study assesses the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion of the P-I/II study will enroll ~360 healthy subjects aged 18-55 and 65-85 yrs.
  • The first person immunized in stage 1 of the study will be healthy adults 18-55 yrs. of age at NYU Grossman School of Medicine and University of Maryland School of Medicine. Additionally, the dosing of the first cohort in Germany was completed last week
  • Both the companies are working to ramp up the manufacturing capabilities for increase production capacity in 2020/2021 and are jointly working globally to commercialize the vaccine upon regulatory approval (excluding China, where BioNTech collaborated with Fosun Pharma for BNT162 for both clinical development and commercialization)

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Africa Health

Related News: 

BioNTech and Pfizer Complete Dosing of BNT162 in First Cohort of P-I/II Study in Germany

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post